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Practical Synthesis of Pharmaceutically Relevant Molecules 
Enriched in sp3 Character 
 
Peter S. Campbell,a Craig Jamieson,*,a Iain Simpson,b and Allan J. B. Watsona
The expedient synthesis of compounds enriched in sp3 character is 
key goal in modern drug discovery. Herein, we report how a single 
pot Suzuki-Miyaura-hydrogenation can be used to furnish lead 
and fragment-like products in good to excellent yields. The 
approach has been successfully applied in formats amenable to 
parallel synthesis, in an asymmetric sense, and in the preparation 
of molecules with annotated biological activity. 
An increasingly important consideration in modern medicinal 
chemistry is control of physicochemical properties with the 
aspi-ration of improving overall quality of candidate drugs.1 In 
relation to this high-level objective, there has been significant 
focus on an increased degree of saturation (i.e. fewer aromatic 
rings) in compound design as this has been linked to increased 
probability of improved physical properties, such as high 
solubility.2 Greater sp3 character bestows three-
dimensionality, which allows molecules to sample a wider area 
of chemical space and potentially achieve superior 
selectivity.2,3 In addition, a higher degree of saturation is 
believed to impart an increased likelihood of clinical success.3 
The overarching design principles discussed above become 
apparent when considering molecules emerging from 
medicinal chemistry laboratories which have fewer aromatic 
rings and are frequently typified by C-aryl linked saturated 
heterocycles represented generally by 1 (Figure 1).  These 
efforts have furnished a range of compounds of this general 
chemotype, and are associated with broad biological activity, 
as illustrated by the exemplar compounds (2  ? 4) shown in 
Figure 1(a).4  
 
Accordingly, efficient methods for the synthesis of molecules 
from this emerging chemotype are currently being actively 
pursued, and typically involve a metal-catalysed cross-coupling 
reaction of an organometallic reagent (boron, zinc, tin or 
magnesium)5-8 with a suitable aryl halide derivative to form 
the sp2-sp3 bond indicated in Figure 1. Despite these efforts, 
some of the currently available methods suffer from a number 
of drawbacks. For example, alkylboron reagents are prone to 
ƉƌŽƚŽĚĞďŽƌǇůĂƚŝŽŶ ĂŶĚ ɴ-hydride elimination.9 Additionally, 
secondary alkylboron reagents have a propensity to isomerize 
during cross coupling, often resulting in inseparable mixtures 
of products.9 Taken as a whole, these issues often preclude the 
application of many of the current methods to synthesize 
target molecules in a high throughput fashion.  
 
 
Figure 1. (a) Biologically active molecules exemplifying the motif of 
interest with key sp2-sp3 bond indicated. (b) Proposed current 
study. 
Since our aim was to furnish biologically relevant frameworks 
with emphasis on 3D character in a manner which was 
amenable to a medicinal chemistry setting, an important 
objective at the outset of our study was that the methodology 
was sufficiently robust to be applicable diverse range of 
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templates. Currently, there is no general consensus on the 
optimal catalyst/ligand combinations that should be utilized in 
these transformations, with cross-coupling protocols often 
requiring a significant degree of optimisation.  Another 
practical consideration in a medicinal chemistry setting is the 
ability to synthesize target compounds in a high-throughput 
manner, meaning that ideally the chemistry selected should be 
sufficiently robust to be amenable to array format, which may 
preclude application of more sensitive reagent and catalyst 
systems.  
 
With these issues in mind, we aimed to develop a robust, one-pot 
Suzuki-Miyaura (SM)-hydrogenation protocol10 to enable facile 
access to molecules of the general chemotype shown in Figure 1(b), 
employing common laboratory reagents, and avoiding the use of 
alkylboron species. From a practical perspective, it was envisaged 
that following Suzuki-Miyaura cross coupling, introduction of a 
suitable hydrogen source could then enable reduction of the newly 
formed olefin 6 in situ, furnishing the desired sp2-sp3 linked system, 
7. Our initial efforts were focused on optimizing the SM component 
of the reaction, followed by investigation into the hydrogenation 
step; however, it was found that the SM conditions employed had a 
significant impact on the extent of hydrogenation. The most 
important factor was the choice of phosphine ligand and the ratio 
of the two palladium catalysts. Upon initial screening, excellent SM 
yields were achieved with minimal optimization. Attention then 
turned to the incorporation of an in situ hydrogenation protocol 
using a Pd/C co-catalyst system as use of the SM catalyst system 
alone was not competent in promoting hydrogenation. Our 
investigation commenced with evacuation of the vessel and 
subsequent addition of a hydrogen source following the initial 
cross-coupling. This was accomplished using hydrogen gas, with a 
6:1 ratio of the two catalysts. Through variation of the palladium 
catalyst to the monodentate PdXPhosG2, and slightly increasing the 
Pd/C loading, the full one-pot process could be achieved with under 
transfer hydrogenation (Table 1, Entry 6), thus rendering the 
transformation amenable to array chemistry (vide infra).  
Having identified optimal conditions, we next sought to explore the 
general applicability of this nascent procedure. In the first instance, 
the scope was examined with respect to the aryl halide coupling 
partner, using the vinyl-piperidine derived system (8) as the 
boronate ester species (Scheme 1). Methyl 4-bromobenzoate 
coupled in excellent yield. Electron-neutral, electron-rich, and 
electron-poor aryl halides were all well tolerated, with ortho, meta, 
and para substitution patterns examined. The reaction manifold 
was also compatible with heterocyclic substrates which are highly 
attractive templates from a medicinal chemistry perspective as they 
are highly lead-like in terms of their physicochemical properties.1,2 
In another aspect of this part of the study, we examined whether 
reducible groups (e.g., nitrobenzene derivatives) or protecting 
groups labile to hydrogenolysis could be concomitantly transformed 
using the newly developed procedure, although this may represent 
a potential limitation of the method if these are required to be 
retained during subsequent synthetic manipulation. 
Table 1. Optimization with respect to catalyst loading and additive.  
Entry Catalyst (1 mol%) Pd/C Hydrogen Source Ratio 
10:9a 
1 Pd(dppf)Cl2.DCMb 6 mol% H2 100:0 
2 Pd(dppf)Cl2.DCMb 6 mol% Et3SiH 74:26 
3 Pd(dppf)Cl2.DCMb 10 mol% Et3SiH 39:61 
4 PdXPhosG2 10 mol% Et3SiH 28:72 
5 PdXPhosG2 10 mol% NH4HCO2 80:20 
6 PdXPhosG2 12 mol% NH4HCO2 100:0 
a determined by 1H NMR. b using K2CO3 as a base. 
The results of this work indicated that nitrobenzene derivatives 
could be reduced to the corresponding aniline systems (11b, 11d), 
while CBz protected amines and benzyl ethers could be removed 
under the reaction conditions, furnishing compounds 11d and 11h, 
respectively, providing additional functionality for further 
derivatization. We then focused our attention on developing a 
protocol which allowed all reactants to be present from the 
reaction outset in order to elevate the practicality of the process. 
Under the standard conditions, addition of ammonium formate at 
the beginning of the reaction posed two problems: 
protodehalogenation of the aryl halide, and reduction (followed by 
protodeboronation) of the vinyl boronate ester, both of which 
inhibited the SM reaction. To circumvent these issues, we took 
inspiration from the work of Buchwald et al.11 by employing a wax 
capsule to physically separate the incompatible reagents. By 
encapsulating ammonium formate in a degradable vessel, the rate 
at which the capsule melted, and thus the release of ammonium 
formate into the system, could be controlled by careful tuning of 
the reaction temperature. Accordingly, the adapted method was 
successfully applied to a series of substrates (11a, 11d, 11m and 
11r), as indicated in Scheme 1. 
Following on from this initial successful demonstration of the utility 
of the process, we sought to apply the conditions developed to a 
broader range of substrates (Scheme 2).  Variation of both coupling 
partners enabled highly efficient access to a raft of different 
substrates, many of which are significantly enriched in sp3 
character. 
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Scheme 1. Lead-like molecules exemplifying the motif of interest 
with key sp2-sp3 bond indicated. 
Additional diversity could be achieved when using more 
functionalized aryl bromide precursors. For example, when ethyl 3-
(5-bromo-2-nitrophenyl)acrylate was used, an efficient in situ 
lactamisation took place, with three reductions and two bond 
forming steps occurring in one pot, yielding 12q and 12r in excellent 
overall yield. We have also demonstrated how application of a 
chiral vinyl bromide substrate can lead to isolation of a fully 
reduced, cross-coupled product in high enantio- and diastereomeric 
purity (12s) and good yield.  The thermodynamically more stable 
trans-product is presumably obtained through a hydritic rather than 
concerted reduction of the alkene.12 To illustrate the practicality of 
this approach in a medicinal chemistry setting, the chemistry was 
applied to an array synthesis format. This allows the preparation of 
multiple sp3-enriched analogues in parallel from commercial 
monomers in a highly efficient manner. We carried out a 4 x 6 array 
with a range of sp2-functionalised organoboron esters and aryl 
bromides which enabled the successful preparation of 23 
compounds, 22 of which were obtained in greater than 50% 
conversion as determined by 1H NMR.   
 
Scheme 2. Variation of both coupling partners with key sp2-sp3 
bond indicated. 
To further underline the utility developed process we also 
examined the synthesis of two bioactive compounds. Firstly, 
pridopidine (3, Scheme 3),4(c) a dopaminergic antagonist, was 
efficiently accessed in 3 steps, which considerably improves upon 
the previously reported synthesis of 7 steps.4(c) Pleasingly, the SM-
hydrogenation step could be also be accomplished in comparable 
yield through use of the encapsulation approach described 
previously. Our second target compound was a 2-amino-3-(5-
methyl-3-hydroxyisoxazol-4-yl)-propanoic acid (AMPA) receptor 
modulator, 15 (Scheme 3).13 Vinyl bromide 14 and biphenyl boronic 
(13) acid were coupled to provide the protected sulfonamide in 71% 
yield, with subsequent acidolysis of the of 2,4-dimethoxybenzyl 
(DMB) group providing the desired compound (15) in high yield.  
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Figure 2. 24-compound array synthesis. 
 
Scheme 3. Application to synthesis of biologically active 
compounds. 
In conclusion, a general and versatile method for formal sp2-sp3 
coupling has been developed which is applicable to a palette of 
substrates representing frameworks of pharmaceutical relevance. 
Computational analysis14 of set shows it has a high mean fraction 
sp3 (fsp3) of 0.52, which ďĂƐĞĚŽŶ>ŽǀĞƌŝŶŐ ?ƐĚĂƚĂ3 is well above the 
high watermark for candidate drugs (mean fsp3 = 0.38 for phase I 
clinical candidates), with the caveat that some of the molecules 
contain protecting groups which may influence the overall average 
fsp3. Successful application of the method in an array format further 
supports its utility in the context of pharmaceutical research and 
development. Work is currently focused on further extension of the 
process towards asymmetry, and will be reported in due course.  
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